glp-1 agonists and sglt2 inhibitors Receptor in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 vs GLP-1 for CKD:

Small peptides like GLP-1 and GLP-2 are rapidly cleared in vivo , leading to low circulating levels

Together, these two incretins contribute to metabolic homeostasis, preventing both hyperglycemia and hypoglycemia, mitigating dyslipidemia, and reducing the risk of cardiovascular diseases in individuals with type 2 diabetes and obesity

Another medication in the works is dapiglutide, a blend of GLP-1 and GLP-2 agonists, and there are more therapies coming down the pike

The GLP-1 Phenomenon: A Metabolic Master Regulator GLP-1 is an incretin hormone produced in the gut in response to food intake

A small Phase 2 trial of 48 adults with alcohol use disorder found that once-weekly semaglutides reduced drinking and cravings over nine weeks compared with placebo